Anx

[السويدي366]

اغلق يوم الجمعه على 1.75

في البري ماركت لحد الان واصل 5.17

انشاء الله رايح فوق

 

[السويدي366]

وللعلم السهم عليه خبر اليوم نزل

 

[m&m]

اغلاق الجمعه الماضي 4.95$ وليس 1.75

 

[السويدي366]

اغلاق الجمعه الماضي 4.95$ وليس 1.75

سوري اغلق على 4.95

هههههههههههههه

 

[السويدي366]

وهذا اول خبر عنه
Press Release Source: ADVENTRX Pharmaceuticals, Inc.


ADVENTRX Presents Positive Thiovir Preclinical Results
Monday April 3, 4:00 am ET


SAN DIEGO, April 3 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX - News) announced today that data were presented showing strong antiviral synergy without added cytotoxicity with combinations of Thiovir(TM) and zidovudine (AZT) in a series of in vitro tests serving as models for human immunodeficiency virus (HIV) infection. The data were presented on Friday, March 31 at the HIV Pathogenesis Meeting, in Keystone, Colorado. The abstract entitled "Synergistic antiviral activity and additive cytotoxicity of Thiovir combined with zidovudine" was presented by Shani Waninger, Ph.D., associate director of research and development for ADVENTRX. Thiovir is a broad spectrum antiviral and oral prodrug for foscarnet, a drug approved to treat opportunistic infections in HIV/AIDS patients. Thiovir is being developed as a reverse transcriptase inhibitor to be used as a component of highly active antiretroviral therapy (HAART) for HIV/AIDS and as a potential antiviral therapy for avian flu.

 

[السويدي366]

وهذيه بعد

4:10AM ADVENTRX Pharma presents positive Thiovir preclinical results (ANX) 4.95 : Co announces that data were presented showing strong antiviral synergy without added cytotoxicity with combinations of Thiovir and zidovudine in a series of in vitro tests serving as models for human immunodeficiency virus infection. The data were presented on Friday, March 31 at the HIV Pathogenesis Meeting, in Keystone, CO. Results were presented from in vitro tests that revealed various combinations of Thiovir and zidovudine showed strong synergistic antiviral activity. This antiviral synergy between Thiovir and zidovudine was significantly more pronounced than antiviral activity of combinations of foscarnet and zidovudine, which were found to be only slightly synergistic to antagonistic. Furthermore, combinations of Thiovir and zidovudine showed less cytotoxicity than combinations of foscarnet and zidovudine, suggesting a safer toxicity profile of the Thiovir and zidovudine combination. Together, these results imply that Thiovir and zidovudine would be compatible as part of an antiviral therapy.

 

[السويدي366]

طبعاً يتكلمون عن اختراع مضادات للايدز وانفونزه الطيور على ما اعتقد